Synact Pharma Ab Stock Retained Earnings
| SYNACT Stock | 20.65 0.65 3.05% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess SynAct Pharma's long-term financial health and intrinsic value.
SynAct |
SynAct Pharma AB Company Retained Earnings Analysis
SynAct Pharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, SynAct Pharma AB has a Retained Earnings of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Retained Earnings (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
SynAct Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SynAct Pharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SynAct Pharma could also be used in its relative valuation, which is a method of valuing SynAct Pharma by comparing valuation metrics of similar companies.SynAct Pharma is currently under evaluation in retained earnings category among its peers.
SynAct Fundamentals
| Return On Equity | -1.49 | |||
| Return On Asset | -0.81 | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 31.82 M | |||
| Shares Owned By Insiders | 36.67 % | |||
| Shares Owned By Institutions | 2.41 % | |||
| Price To Book | 26.57 X | |||
| EBITDA | (76.62 M) | |||
| Net Income | (76.7 M) | |||
| Book Value Per Share | 2.82 X | |||
| Cash Flow From Operations | (65 M) | |||
| Target Price | 120.0 | |||
| Beta | 0.69 | |||
| Market Capitalization | 2.42 B | |||
| Total Asset | 38.37 M | |||
| Z Score | -3.3 | |||
| Net Asset | 38.37 M |
About SynAct Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SynAct Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SynAct Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SynAct Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in SynAct Stock
SynAct Pharma financial ratios help investors to determine whether SynAct Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SynAct with respect to the benefits of owning SynAct Pharma security.